HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus.

AbstractOBJECTIVE:
We herein examine the role of endogenous miR155 in the development of systemic manifestations in pristane induced lupus.
MATERIALS AND METHODS:
Systemic lupus in miR155-deficient and wild type mice was induced upon injection of pristane and analyzed after 8 months, PBS-injected mice served as controls. Glomerulonephritis and pneumonitis were quantified using the kidney biopsy score and a newly adapted histomorphometric image analysis system; lung tissue was further analyzed by tissue cytometry. Serum levels of anti-dsDNA, anti-histone and anti-chromatin antibodies were measured by ELISA. Frequencies of B cells, activated and regulatory CD4+ T cells as well as Th1, Th2, Th17 cells were measured by flow cytometry. RT-qPCR was used to measure expression levels of interferon-signature and T-cell subset related as well as miR155-associated genes.
RESULTS:
After induction of lupus, miR155-deficient mice had significant less pulmonary involvement (perivascular inflammatory area in mm2/mm2 lung area 0.00092±0.00015 vs. 0.0027±0.00075, p = 0.0347) and renal disease (glomerular activity score 1.95±0.19 vs 3±0.26, p = 0.0029) compared to wild types. MiR155-deficient mice had significantly lower serum levels of disease-associated auto-antibodies and decreased frequencies of activated CD4+CD25+ (Foxp3-) cells. Upon restimulation, CD4+ cells showed a less pronounced Th2 and Th17 and a slightly decreased Th1 response in mir155-deficient mice. Pristane-treated wild types showed significantly up-regulated expression of genes related to the INF-signature (MX1, IP10, IRF7, ISG15).
CONCLUSIONS:
MiR155-deficient mice had less severe organ involvement, lower serum auto-antibody levels, a less prominent T cell response and lower expressions of genes jointly responsible for disease development. Thus, antagonizing miR155 might be a future approach in treating SLE.
AuthorsHarald Leiss, Wilhelm Salzberger, Barbara Jacobs, Irina Gessl, Nicolas Kozakowski, Stephan Blüml, Antonia Puchner, Attila Kiss, Bruno K Podesser, Josef S Smolen, Georg H Stummvoll
JournalPloS one (PLoS One) Vol. 12 Issue 7 Pg. e0181015 ( 2017) ISSN: 1932-6203 [Electronic] United States
PMID28719617 (Publication Type: Journal Article)
Chemical References
  • Autoantibodies
  • MicroRNAs
  • Mirn155 microRNA, mouse
  • Terpenes
  • pristane
  • Interferons
Topics
  • Animals
  • Autoantibodies (metabolism)
  • Gene Expression Regulation (drug effects, immunology)
  • Interferons (metabolism)
  • Kidney (drug effects, immunology)
  • Lung (drug effects, immunology)
  • Lupus Erythematosus, Systemic (chemically induced, complications)
  • Mice
  • MicroRNAs (metabolism)
  • Nephritis (complications, drug therapy, immunology, metabolism)
  • Pneumonia (complications, drug therapy, immunology, metabolism)
  • T-Lymphocyte Subsets (drug effects, immunology)
  • Terpenes (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: